A one-time treatment using CRISPR gene-editing technology has demonstrated the ability to effectively lower levels of LDL and triglycerides for extended periods, according to a recent study. The therapy targets the ANGPTL3 gene in liver cells, which play a crucial role in producing cholesterol and triglycerides.
Researchers observed that individuals receiving the CRISPR therapy maintained lower lipid levels for up to a year. This durability suggests that the gene editing successfully modified a sufficient number of liver cells to provide lasting benefits. In participants who received the highest dose, levels of the ANGPTL3 enzyme decreased by nearly 80%, leading to an approximate 50% reduction in LDL and triglycerides.
Dr. Luke Laffin, lead author of the study and co-director of the Center for Blood Pressure Disorders at the Cleveland Clinic, described the results as a significant step for CRISPR technology, showcasing the durability of its effects. The therapy was found to be well-tolerated, with no significant side effects reported. This finding aligns with observations of individuals born with a defective ANGPTL3 gene, who generally do not experience serious health issues.
This development could potentially offer an alternative to the current standard treatment, which involves taking statin pills daily. While statins are effective, adherence to daily medication regimens over many years can be challenging, diminishing their overall impact. Laffin suggested that in the future, this one-time gene-editing therapy could become an option for individuals with a strong family history of heart disease or high cholesterol, providing a way to manage their lipid levels through a single treatment that modifies their liver cells for long-term benefit.